The Board of Directors of ReWalk Robotics Ltd. increased the size of the board from eight to nine members, and recently appointed Joseph Turk ’89 as a Class I Director of the Company. ReWalk is a leading manufacturer of robotic medical technology for people with lower extremity disabilities.
Turk’s appointment took effect In April, and he will serve on the board until 2024.
Turk has assembled an extensive history in the medical device industry beginning with his role as director of New Business Development at Boston Scientific. Subsequently, he held multiple roles at NxStage Medical, including president, where he led all commercialization activities including securing favorable Medicare payment policies; overseeing all commercial functions for the implementation and growth of their key products; and coordinating key M&A efforts for building the company, according to a news release. Currently, he is an executive vice president at Fresenius Medical Care North America (FMC-NA) and the president of the Renal Therapies Group.
“Being able to improve people’s lives through commercializing novel technologies has been a driving force in my career,” Turk said. “Working with a mission-driven company with life-changing technologies such as ReWalk is a natural fit. I look forward to contributing my insight to help ReWalk develop successful broad commercialization strategies that enable better health for the disabled community, all within the context of a sustainable business model.”
Turk holds a B.A. from Wabash College and an M.A from the Kellogg Graduate School of Management. While at Wabash, he majored in economics and was a member of Beta Theta Pi fraternity.
